Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tavocept for Prevention of Paclitaxel Neurotoxicity in Metastatic Breast Cancer
NCT00039780Phase 3Completed
- Sponsor
- BioNumerik Pharmaceuticals
- Start
- Sep 2001
- Primary completion
- Oct 2006
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, double-blind trial in peripheral neuropathy comparing Tavocept Arm with Placebo Arm (2 arms). Primary endpoints: Incidence of Patient Neuropathy Questionnaire Grade D or Grade E neurosensory symptoms at 4 weeks and Objective Tumor Response Rate. Started Sep 2001; status: completed.
02
Drugs
dimesna
03
Conditions
peripheral neuropathy
Beyond the preview
Go deeper on NCT00039780.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00039780.